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Frailty and the Burden of Concurrent 
and Incident Disability in Patients With 
Cirrhosis: A Prospective Cohort Study
Jennifer C. Lai ,1 Jennifer L. Dodge,2 Charles E. McCulloch,3 Kenneth E. Covinsky,1 and Jonathan P. Singer1
Frailty results from the chronic effects of malnutrition and muscle wasting in patients with cirrhosis. It is well- 
established that frailty is strongly associated with mortality in this population. However, little is known of its rela-
tionship with physical disability, a critical patient-centered outcome. Adults with cirrhosis underwent outpatient 
testing of frailty using the Liver Frailty Index (LFI) and disability using activities of daily living (ADL; range 0-6) 
and Instrumental ADL (IADL; range 0-8) scales at one center between 2012 and 2016. We used adjusted multi-
level logistic mixed-effects regression to test the association between frailty and current disability (impairment with ≥1 
ADL or IADL) and incident disability at 6  months among those without baseline disability. Of the 983 participants, 
20% were robust, 32% were less robust, 33% were prefrail, and 15% were frail; 587 (60%) had at least 1 assessment. 
The percentage of participants with at least 1 baseline ADL or IADL impairment was 28% and 37%, respectively. In 
adjusted regression models, each point LFI increase was associated with a 3.3 and 4.6 higher odds of current difficulty 
with at least 1 ADL and IADL (P  <  0.001 for each), respectively. Among participants without baseline disability, each 
point LFI increase was associated with a 2.6 and 1.7 higher odds of having difficulty with at least 1 ADL and IADL 
at 6  months, respectively. Conclusion: Frailty is strongly associated with concurrent and incident disability in patients 
with cirrhosis. In the clinic, the LFI can be used to identify those in greatest need for additional support/resources to 
maintain functional independence. In research settings, the LFI may help to identify an enriched population for clinical 
trials of interventions aimed at those most vulnerable to disability. (Hepatology Communications 2020;4:126-133).
In most patients with cirrhosis, chronic undernu-trition and muscle loss manifest as physical frailty to at least some degree.(1,2) In 2017, we developed 
the Liver Frailty Index (LFI) to objectively capture 
these insidious (and sometimes lethal) conditions. 
Consisting purely of performance-based tests, the 
LFI enhances risk prediction above and beyond tradi-
tional, well-known predictors of mortality in patients 
with cirrhosis, including the Model for End-Stage 
Liver Disease ascites–sodium (MELD-Na), hepatic 
encephalopathy, and age.(3-5)
Although the three components of the LFI (grip 
strength, chair stands, and balance) intuitively contrib-
ute to functional independence (i.e., the ability to live 
without the assistance of other people), its relationship 
with functional independence, or lack thereof, has not 
yet been directly characterized. In the field of geriat-
rics, difficulty or dependency in carrying out activities 
essential to independent living (e.g., self-care, home 
care, food preparation, transportation management) is 
defined as “disability.” Although the concepts of dis-
ability and physical frailty are interrelated, they can 
Abbreviations: ADL, activities of daily living; CI, conf idence interval; IADL, instrumental activities of daily living; LFI, Liver Frailty Index; 
MELD-Na, Model for End-Stage Liver Disease ascites–sodium.
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be observed independently of one another.(6) Both 
frailty and disability are widely recognized as potent 
predictors of mortality. Beyond predicting mortality, 
however, disability is also a fundamentally important 
outcome in and of itself.(7-9) In fact, the World Health 
Organization has identified disability as a major 
health issue that is responsible for more than half the 
burden of premature mortality.(10) Furthermore, the 
Patient-Centered Outcomes Research Institute recog-
nizes the preservation of functional independence as a 
fundamental goal of medical care that is important to 
patients themselves.(11)
Using this prior work in the field of geriatrics as 
the scientific premise for our study, we aimed to eval-
uate the relationship between physical frailty and dis-
ability in patients with cirrhosis.
Patients and Methods
stuDy population
We used longitudinally collected data from par-
ticipants enrolled in the Functional Assessment in 
Liver Transplantation (FrAILT) study from March 
2012 through December 2016; the full FrAILT Study 
protocol has been published previously.(3) Briefly, 
adult outpatients with cirrhosis who were actively 
listed for liver transplantation at the University of 
California, San Francisco, were eligible for enroll-
ment. Participants underwent study procedures (see 
subsequently) at enrollment and at every clinic visit. 
The timing of the clinic visits was determined at the 
discretion of the primary hepatologist, although gen-
eral practice is to see patients awaiting liver trans-
plantation every 3 to 6  months. For the purposes of 
this study, participants were followed through August 
2018 or until they experienced a terminal wait-list 
event (such as transplant, death, or removal from the 
transplant list for other reasons).
stuDy pRoCeDuRes
All participants underwent objective measurement 
of frailty using the following tests: (1) grip strength: 
the average of three trials, measured in the subject’s 
dominant hand using a hand dynamometer; (2) timed 
chair stands: measured as the number of seconds it 
takes to do five chair stands with the subject’s arms 
folded across the chest; and (3) balance testing: 
measured as the number of seconds that the subject 
can balance in three positions (feet placed side-to-
side, semi-tandem, and tandem) for a maximum of 
10 seconds each.
These three tests were administered by trained study 
personnel. With these three individual tests of frailty, 
the LFI was calculated using the following equation(3) 
(calculator available at http://liver frail tyind ex.ucsf.edu):
On the same day as the frailty assessment, we 
assessed disability using two validated scales: (1) 
activities of daily living(12) (ADLs) and (2) instru-
mental ADLs (IADLs).(13) ADLs consist of six 
activities: bathing, dressing, toileting, transferring, 
continence, and feeding. IADLs consist of eight activ-
ities distinct from the six ADLs: using a telephone, 
shopping, food preparation, housekeeping, doing 
laundry, transportation, managing finances, and man-
aging medications. For each activity, study personnel 
asked through verbal interviews, “Do you have diffi-
culty with _________?” Participants were considered 
to have disability in a particular ADL/IADL if they 
(− 0.330∗gender-adjusted grip strength)
+ (−2.529∗number of chair stands per second)
+ (−0.040∗balance time) + 6
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answered yes to that question. The maximum num-
ber of affirmative responses for ADLs was six, and for 
IADLs was eight.
Demographic data were extracted from the clinic 
visit note from the same day as the LFI and disability 
assessments. Participants were considered to have a 
diagnosis of hypertension, diabetes, or coronary artery 
disease if reported in their electronic health record. 
Ascites was ascertained at each study visit from the 
hepatologist’s recorded physical exam or the manage-
ment plan associated with the clinic visit that occurred 
on the same day at the assessment of frailty. Ascites 
was categorized as “absent” if ascites was not present 
on physical exam or “present” if ascites was present on 
exam and/or the participant was noted to be under-
going large-volume paracenteses. Hepatic encepha-
lopathy was determined at each study visit from the 
time to complete the Numbers Connection Test A(14) 
performed at the time of the frailty measurement. 
Hepatic encephalopathy was categorized as “present” 
if the participant took 45 or more seconds to complete 
the task. This cutoff of 45 seconds was selected based 
on normative data determined from healthy partici-
pants and compared with individuals with and with-
out hepatic encephalopathy.(14)
statistiCal analysis
Baseline demographics were presented as medi-
ans (interquartile ranges) for continuous variables or 
percentages for categorical variables and compared by 
frailty status using Kruskal-Wallis or chi-square tests 
with exact methods as needed. Trends by frailty status 
were assessed using ordinary least-squares regression 
or the Cochran-Armitage trend test. The primary 
outcome was disability using ADL (range 0-6) and 
IADL (range 0-8) scales; disability was defined as 
difficulty with at least 1 ADL or at least 1 IADL, 
each corresponding to the presence of at least one dis-
ability. Frailty was categorized as robust, less robust, 
prefrail, and frail using established LFI cut-off points: 
fewer than 3.2, 3.2-3.7, 3.8-4.4, and 4.5 or more.(3)
Multilevel mixed-effects logistic regression mod-
eled longitudinal data from each clinic visit to evaluate 
the association between the LFI and (1) current dis-
ability among all participants and (2) incident disabil-
ity at 6 months (±2 months) among participants with 
no disability at baseline (ADL = 6 or IADL = 8). This 
6-month time frame for the outcome was selected to 
facilitate clinical interpretation. In these models, a 
single participant could contribute multiple obser-
vations such that the LFI was modeled as a time- 
dependent predictor. We structured the models with 
two levels (participant and visit), nesting the longitu-
dinal visit-level observations within the participant to 
address correlation. Baseline age and gender, as well 
as time-varying LFI, MELD, hepatic encephalopa-
thy, ascites, body mass index and time, were modeled 
as fixed effects. These characteristics were selected 
beforehand and included in the multivariable models, 
regardless of statistical significance, given their biolog-
ically plausible associations with frailty. A participant 
was modeled as a random effect to allow for random 
intercepts. Random slopes were also assessed but did 
not improve the model fit. From the multivariable 
models, we calculated the predicted probabilities of 
incident disability at specific LFI values while holding 
covariates at the mean.
Data analysis was completed using SAS version 9.4 
(SAS Institute, Cary, NC) and Stata/IC version 14.2 
(StataCorp, College Station, TX).
Results
A total of 983 participants with cirrhosis were 
included in the analyses: at baseline, 197 (20%) were 
robust (LFI  <  3.2), 312 (32%) were less robust (LFI 
3.2-3.7), 323 (33%) were prefrail (LFI 3.8-4.4), and 
151 (15%) were frail (LFI ≥ 4.5). Baseline character-
istics of the cohort are found in Table 1. The groups 
were clinically similar in age and proportion with 
hypertension or coronary artery disease. The groups 
differed by proportion who were female, race/ethnicity, 
etiology of liver disease, HCC, diabetes, and body 
mass index. Metrics of liver disease severity increased 
as frailty increased, including MELD-Na scores and 
prevalence of ascites and hepatic encephalopathy (test 
of trend P < 0.001 for each). Median follow-up time 
was longer in the robust and prerobust participants 
than the prefrail and frail participants.
CRoss-seCtional assoCiation 
BetWeen tHe lFi anD CuRRent 
DisaBility
The proportion of participants who had difficulty 
with at least one ADL or with at least one IADL 
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at baseline was 28% and 37%, respectively. For both 
ADLs and IADLs, this proportion increased with 
worsening LFI category (test of trend P  <  0.001 for 
both). For ADLs, the proportions were 11% for robust, 
18% for prerobust, 35% for prefrail, and 56% for frail. 
For IADLs, the proportions were 15% for robust, 
23% for prerobust, 46% for prefrail, and 75% for frail. 
These observations remained for each individual ADL 
(Fig. 1) and IADL (Fig. 2) (test of trend P ≤ 0.001 in 
all cases). In adjusted multilevel mixed-effects logistic 
regression analyses, each one-unit increase in the LFI 
(i.e., worsening) was associated with a 3.3-fold higher 
odds of reporting difficulty with at least 1 ADL (95% 
confidence interval [CI], 2.7-4.1; P  <  0.001) and a 
4.6-fold higher odds of reporting difficulty with at 
least 1 IADL (95% CI, 3.6-6.0; P < 0.001).
assoCiation BetWeen tHe lFi 
anD FutuRe DisaBility
A total of 587 participants had at least two assess-
ments of both frailty and disability. Comparison 
of the characteristics of those with only one assess-
ment versus more than one assessment are presented 
in Supporting Table S1. Participants in our cohort 
with only one assessment were similar to those with 
more than one assessment in demographic charac-
teristics but, as expected, were sicker by liver disease 
taBle 1. CHaRaCteRistiCs oF tHe 983 stuDy paRtiCipants inCluDeD in tHis stuDy
By Frailty Phenotype
Test of Trend 
P Value
All Robust Prerobust Prefrail Frail
Characteristics* n = 983 n = 297 (30%) n =3 12 (32%) n = 323 (33%) n = 151 (15%)
Age, years 60 (53-64) 59 (51-63) 60 (55-64) 60 (54-64) 59 (51-64) 0.07
Women 34% 25% 33% 36% 43% <0.001
Race/Ethnicity
Non-Hispanic white 57% 64% 55% 53% 56% 0.04
Black 4% 4% 4% 5% 2% 0.46
Hispanic 24% 17% 23% 28% 30% <0.001
Asian/Pacific Islander 7% 9% 10% 6% 3% 0.02
Other 8% 6% 8% 8% 10% 0.16
Body mass index, kg/m2 28 (25-32) 27 (24-31) 28 (25-32) 29 (25-33) 29 (25-34) <0.001
Etiology of liver disease
Chronic hepatitis C 49% 53% 57% 47% 33% <0.001
Alcohol 18% 15% 13% 22% 26% <0.001
Nonalcoholic steatohepatitis 11% 7% 8% 13% 20% <0.001
Autoimmune/cholestatic 10% 12% 12% 9% 8% 0.09
Other 11% 14% 10% 9% 13% 0.63
Hepatocellular carcinoma 37% 46% 43% 35% 16% <0.001
Hypertension 42% 38% 41% 46% 40% 0.38
Diabetes 28% 20% 27% 29% 40% <0.001
Coronary artery disease 6% 5% 6% 8% 3% 0.96
MELD-Na 17 (13-21) 15 (12-19) 16 (12-19) 17 (14-22) 21 (16-26) <0.001
Creatinine, mg/dL† 0.9 (0.7-1.2) 0.8 (0.7-1.0) 0.9 (0.7-1.2) 0.9 (0.7-1.2) 1.1 (0.8-1.6) <0.001
Dialysis 4% 2% 2% 4% 9% <0.001
Albumin, g/dL 3.1 (2.7-3.6) 3.4 (2.9-3.8) 3.1 (2.7-3.6) 3.0 (2.6-3.4) 3.0 (2.5-3.4) <0.001
Ascites 27% 12% 23% 31% 47% <0.001
Hepatic encephalopathy 39% 18% 37% 48% 54% <0.001
Follow up time, months 9.8 (4.4-18.4) 11.9 (4.9-20.5) 10.5 (5.6-18.4) 7.9 (4.2-16.6) 9.0 (3.7-16.4) 0.04
*Median (interquartile range) or percentage.
†Among those who were not on dialysis.
Hepatology CommuniCations, January 2020LAI ET AL.
130
severity (MELD-Na). Wait-list outcomes were simi-
lar between the two groups (P = 0.77).
Among those with at least two assessments, 
higher categories of baseline LFI values were asso-
ciated with increasing proportions of participants 
who experienced worsening of at least one ADL at 
a subsequent study visit. Specifically, the proportion 
of robust, prerobust, prefrail, and frail participants 
who experienced subsequent worsening in their 
ADLs was 21%, 35%, 40%, and 50% (test of trend 
P  < 0.001). Similarly, the proportion of participants 
who experienced any worsening in their IADLs at 
a subsequent assessment increased with worsening 
frailty category: 23% for robust, 36% for prerobust, 
40% for prefrail, and 52% for frail (test of trend 
P < 0.001).
assoCiation BetWeen tHe 
lFi anD FutuRe DisaBility 
among tHose WitHout any 
DisaBility at Baseline
Finally, given the clinical relevance of transitioning 
from complete independence in ADLs or IADLs to 
having any disability in ADLs or IADLs, we per-
formed secondary analyses in only those participants 
who had no disability at baseline and had a second 
assessment at 6 months (±2 months). For ADLs, we 
analyzed 595 assessments among 294 participants, 
and for IADLs, we analyzed 524 assessments among 
265 participants.
In multilevel mixed-effects logistic regression, each 
one-unit increase in the LFI was associated with a 
Fig. 1. Proportion of patients with difficulty with each ADL at baseline, by frailty category (test of trend P ≤ 0.001 for each).
Fig. 2. Proportion of patients with difficulty with each IADL at baseline, by frailty category (test of trend P < 0.001 for each).
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2.6-fold higher adjusted odds of developing subse-
quent difficulty with at least one ADL at 6  months 
(95% CI, 1.4-4.6; P  =  0.001) and a 1.7-fold higher 
adjusted odds of developing subsequent difficulty 
with at least one IADL (95% CI, 1.0-2.9; P = 0.05). 
Figure 3 shows the predicted probabilities of incident 
ADL and IADL disability at 6 months. For example, 
at LFI values of 3.0, 4.0, and 5.0, the predicted proba-
bilities (95% CI) for 6-month incident disability in at 
least one ADL are 13% (9%-18%), 23% (17%-29%), 
and 36% (23%-49%), and the predicted probabilities 
for 6-month incident disability in at least one IADL 
are 12% (8%-16%), 17% (12%-22%), and 24% (12%-
39%) (Fig. 3a).
Discussion
When the cure or reversal of a disease process 
is not feasible, the goal of medical care is to reduce 
patient suffering through treatments that optimize 
functioning, reduce disability, and improve health- 
related quality of life. Cirrhosis is a quintessential 
example of a condition for which there is no cure, 
except for liver transplantation, which is accessible to 
only a minority of those with end-stage liver disease.(15) 
Yet, to date, the biomedical literature on treatment for 
cirrhosis and its complications is largely focused on the 
outcomes of liver disease progression and/or mortal-
ity. Although these outcomes are critically important, 
quantifying the burden of cirrhosis on patients’ daily 
life beyond disease progression and death is crucial 
to developing strategies to improve the quality and 
patient-centeredness of care.
With this in mind, we offer several observations 
from this study. First, the observed that rates of dis-
ability were unexpectedly high for an outpatient pop-
ulation with a median age of only 60  years. Indeed, 
28% of participants reported disability in at least 
one ADL and 37% reported disability in at least 
one IADL. Our findings are similar to a sample of 
about 300 individuals with cirrhosis in the national 
Health and Retirement Study.(16) To contextualize 
our findings, approximately 3%-10% of more than 
8,000 community-dwelling older adults (age range: 
65-90+  years) participating in the National Health 
and Aging Trends Study reported impairment with 
any one ADL (rate varied by individual ADL).(17) 
Second, frailty, as measured by the LFI, was strongly 
associated with current disability with both ADLs 
and IADLs. In fact, the proportion of participants 
reporting disability in ADLs and IADLs increased in 
a stepwise fashion as frailty worsened. Lastly, among 
those who were not disabled at baseline, frailty was 
strongly associated with the development of future 
disability in both ADLs and IADLs.
Although notable, our findings likely underesti-
mate the burden of cirrhosis on the lived experience 
of our patients, as the ADL and IADL disability 
scales quantify advanced physical disabilities. Indeed, 
a person in need of help with an ADL is unable to 
live alone without assistance on a daily basis. A per-
son in need of help with an IADL will have diffi-
culty living alone or, at the very least, have impaired 
Fig. 3. Predicted probability of incident disability, defined as difficulty with at leat one ADL or IADL at 6 months, by baseline LFI, 
among patients with no reported disability at a prior assessment.
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health-related quality of life without regular assistance. 
The ADL and IADL scales are crude measures of dis-
ability in younger ambulatory populations, as there are 
often floor effects in which most patients score “well” 
and do not appear to change over time. By the time 
impairment in an ADL or IADL develops, patients 
have long been disabled in other, more discretionary 
activities that require less effort. As a disease increas-
ingly affects physical performance and energy, people 
will often first sacrifice “discretionary” activities that 
provide pleasure and give life meaning in order to pre-
serve their capacity to perform those activities required 
for survival within their home (ADL) and their com-
munity (IADL). While we did not directly measure 
health-related quality of life in our study, the ability to 
perform such activities are essential to one’s quality of 
life; therefore, the development of ADL or IADL dif-
ficulty may serve as a surrogate for impaired quality of 
life. Our data demonstrating high rates of ADL and 
IADL disability in relatively young adults with cirrho-
sis should raise awareness of the enormous burden of 
disability in this population. Our data also suggest that 
routinely assessing disability and addressing disability 
could result in marked improvements in patient out-
comes, as has been shown in the field of geriatrics.
However, the main barriers to using patient- 
reported scales in measuring patient-oriented out-
comes such as disability or health-related quality of 
life are the instruments’ subjectivity and limited ability 
to predict future outcomes. This is a particularly rele-
vant barrier in the field of hepatology, in which many 
patients with end-stage liver disease may ultimately 
become candidates for liver transplantation, when 
objectivity of risk assessment is paramount. The LFI, 
a reliable, reproducible, performance-based metric that 
can be administered by medical assistants in approx-
imately 90  seconds,(18) can help to identify patients 
with concurrent and future risk for subsequent ADL 
and IADL disability beyond what is routinely col-
lected as part of today’s standard clinical practice.
We acknowledge that our study is limited by the 
fact that we only assessed patients at their regular 
outpatient clinic visit; not all patients had more than 
one assessment. Although this would not affect anal-
yses evaluating the association between the LFI and 
current disability, it is possible that this could intro-
duce bias in the analyses of longitudinal assessments. 
Our use of multilevel mixed-effects modeling allowed 
us to account for intrapatient characteristics that 
were similar from one observation to another, and 
our secondary analyses evaluating only those with an 
assessment at 6  months (±2  months), may minimize 
the influence of differential, nonrandom follow-up. 
Second, our cohort included only patients at a sin-
gle center, which could potentially limit the general-
izability of these data to other populations. Finally, 
the development and reporting of disability may be 
influenced by one’s culture and native language; our 
study may not be broadly applicable to patients who 
identify as races that are relatively underrepresented 
in this study.
Despite these limitations, our study is the largest 
study to evaluate disability in patients with cirrhosis, 
a fundamentally important patient-centered outcome. 
Our observation that the LFI is strongly associated 
with current and subsequent disability has important 
implications for the hepatology community. Routine 
assessment of patients with cirrhosis using the LFI in 
the outpatient clinical setting can help to quickly iden-
tify those who are most vulnerable to disability, and 
therefore in greatest need of more supportive services. 
These services might be more frequent follow-up, tar-
geted exercise programs, multidisciplinary outpatient 
chronic disease management, or in-home services, as 
has been shown to be effective in individuals with other 
disabling conditions.(19-22) Furthermore, the Food and 
Drug Administration emphasizes patient-focused 
drug development for selecting outcomes in interven-
tional trials. They recommend including measures of 
how a patient “feels or functions.”(23) Given its asso-
ciation with both mortality and disability, the LFI 
should be considered for validation as a surrogate end-
point in clinical trials with respect to patient-oriented 
outcomes. The LFI may further facilitate efficient trial 
design by allowing investigators to identify study par-
ticipants who could most benefit from certain inter-
ventions. If the focus of care of patients with cirrhosis 
is to reduce suffering, then we, as a community, must 
begin to introduce the tools to assess current disability 
and risk for progressive disability into our clinical and 
research settings.
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